141 related articles for article (PubMed ID: 33399479)
21. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
[TBL] [Abstract][Full Text] [Related]
22. CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.
Perwitasari DA; Irham LM; Darmawan E; Mulyani UA; Atthobari J
Indian J Tuberc; 2016 Jul; 63(3):139-143. PubMed ID: 27865233
[TBL] [Abstract][Full Text] [Related]
23. Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Bozok Cetintaş V; Erer OF; Kosova B; Ozdemir I; Topçuoğlu N; Aktoğu S; Eroğlu Z
Tuberk Toraks; 2008; 56(1):81-6. PubMed ID: 18330759
[TBL] [Abstract][Full Text] [Related]
24. Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.
Singh N; Dubey S; Chinnaraj S; Golani A; Maitra A
Mol Diagn Ther; 2009; 13(1):49-58. PubMed ID: 19351215
[TBL] [Abstract][Full Text] [Related]
25. Studies on N-Acetyltransferase (NAT2) Genotype Relationships in Emiratis: Confirmation of the Existence of Phenotype Variation among Slow Acetylators.
Al-Ahmad MM; Amir N; Dhanasekaran S; John A; Abdulrazzaq YM; Ali BR; Bastaki S
Ann Hum Genet; 2017 Sep; 81(5):190-196. PubMed ID: 28653770
[TBL] [Abstract][Full Text] [Related]
26. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.
Yuliwulandari R; Sachrowardi Q; Nishida N; Takasu M; Batubara L; Susmiarsih TP; Rochani JT; Wikaningrum R; Miyashita R; Miyagawa T; Sofro ASM; Tokunaga K
J Hum Genet; 2008; 53(3):201-209. PubMed ID: 18160997
[TBL] [Abstract][Full Text] [Related]
28. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Thomas L; Raju AP; Chaithra ; M SS; Varma M; Saravu K; Banerjee M; Sv CS; Mallayasamy S; Rao M
Eur J Clin Pharmacol; 2022 Oct; 78(10):1535-1553. PubMed ID: 35852584
[TBL] [Abstract][Full Text] [Related]
29. Influence of
Thomas L; Raju AP; Chaithra S; Kulavalli S; Varma M; Sv CS; Baneerjee M; Saravu K; Mallayasamy S; Rao M
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):263-274. PubMed ID: 38287694
[TBL] [Abstract][Full Text] [Related]
30. Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
Igumnova V; Capligina V; Krams A; Cirule A; Elferts D; Pole I; Jansone I; Bandere D; Ranka R
J Infect Chemother; 2016 Jul; 22(7):472-7. PubMed ID: 27236516
[TBL] [Abstract][Full Text] [Related]
31. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
32. Genomewide Association Study Confirming the Association of
Suvichapanich S; Wattanapokayakit S; Mushiroda T; Yanai H; Chuchottawon C; Kantima T; Nedsuwan S; Suwankesawong W; Sonsupap C; Pannarunothai R; Tumpattanakul S; Bamrungram W; Chaiwong A; Mahasirimongkol S; Mameechai S; Panthong W; Klungtes N; Munsoo A; Chauychana U; Maneerat M; Fukunaga K; Omae Y; Tokunaga K
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109976
[TBL] [Abstract][Full Text] [Related]
33. Full-gene-sequencing analysis of N-acetyltransferase-2 in an adult Indian population.
Tilak AV; Iyer SN; Mukherjee MS; Singhal RS; Lele SS
Genet Test Mol Biomarkers; 2013 Mar; 17(3):188-94. PubMed ID: 23216273
[TBL] [Abstract][Full Text] [Related]
34. Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs.
Costa GN; Magno LA; Santana CV; Konstantinovas C; Saito ST; Machado M; Di Pietro G; Bastos-Rodrigues L; Miranda DM; De Marco LA; Romano-Silva MA; Rios-Santos F
Mol Diagn Ther; 2012 Aug; 16(4):241-50. PubMed ID: 22788240
[TBL] [Abstract][Full Text] [Related]
35. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
36. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients.
Mushiroda T; Yanai H; Yoshiyama T; Sasaki Y; Okumura M; Ogata H; Tokunaga K
Hum Genome Var; 2016; 3():16014. PubMed ID: 27340556
[TBL] [Abstract][Full Text] [Related]
37. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.
Guaoua S; Ratbi I; Laarabi FZ; Elalaoui SC; Jaouad IC; Barkat A; Sefiani A
BMC Genet; 2014 Dec; 15():156. PubMed ID: 25544508
[TBL] [Abstract][Full Text] [Related]
38. Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA; Kandeel M; Aldossary SA; Al-Taher A
Biomed Res Int; 2020; 2020():8765347. PubMed ID: 32626768
[TBL] [Abstract][Full Text] [Related]
39. Relevance of
Cheng F; Qiu CC; Jiang XG; Wu T; Zhang Q; Chen X; Zheng SL; Liu SD; Ye XC; Shi JC
Pharmacogenomics; 2024 Jan; 25(1):21-28. PubMed ID: 38131213
[TBL] [Abstract][Full Text] [Related]
40. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
